ZA201001477B - Methods of enhancing adjuvanticity of vaccine compositions - Google Patents

Methods of enhancing adjuvanticity of vaccine compositions

Info

Publication number
ZA201001477B
ZA201001477B ZA2010/01477A ZA201001477A ZA201001477B ZA 201001477 B ZA201001477 B ZA 201001477B ZA 2010/01477 A ZA2010/01477 A ZA 2010/01477A ZA 201001477 A ZA201001477 A ZA 201001477A ZA 201001477 B ZA201001477 B ZA 201001477B
Authority
ZA
South Africa
Prior art keywords
adjuvanticity
enhancing
methods
vaccine compositions
vaccine
Prior art date
Application number
ZA2010/01477A
Other languages
English (en)
Inventor
Vincent Serra
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax filed Critical Abivax
Publication of ZA201001477B publication Critical patent/ZA201001477B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ZA2010/01477A 2007-08-29 2010-03-01 Methods of enhancing adjuvanticity of vaccine compositions ZA201001477B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96873107P 2007-08-29 2007-08-29
PCT/IB2008/003016 WO2010023498A1 (en) 2007-08-29 2008-08-29 Methods of enhancing adjuvanticity of vaccine compositions

Publications (1)

Publication Number Publication Date
ZA201001477B true ZA201001477B (en) 2010-12-29

Family

ID=42061962

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/01477A ZA201001477B (en) 2007-08-29 2010-03-01 Methods of enhancing adjuvanticity of vaccine compositions

Country Status (14)

Country Link
US (1) US8916164B2 (enExample)
EP (1) EP2190475B1 (enExample)
JP (1) JP5539890B2 (enExample)
KR (1) KR101540081B1 (enExample)
CN (1) CN101820909A (enExample)
AU (1) AU2008360937B9 (enExample)
BR (1) BRPI0815846A2 (enExample)
ES (1) ES2558157T3 (enExample)
HR (1) HRP20151356T1 (enExample)
PL (1) PL2190475T3 (enExample)
PT (1) PT2190475E (enExample)
RU (1) RU2491090C2 (enExample)
WO (1) WO2010023498A1 (enExample)
ZA (1) ZA201001477B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0820960B8 (pt) 2007-12-05 2021-05-25 Abivax composição, composição farmacêutica, e uso da composição
MY171201A (en) 2012-04-26 2019-10-01 Riken New carbamate glycolipid and use thereof
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242800A (en) 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (enExample) 1992-07-16 1995-11-01 Kirin Brewery
ATE191916T1 (de) 1992-10-22 2000-05-15 Kirin Brewery Neues sphingolglycolipid und verwendung davon
US5780441A (en) 1993-04-15 1998-07-14 Kirin Beer Kabushiki Kaisha Sphingoglycolipid compounds and therapeutic uses thereof
CN1125449A (zh) 1993-05-14 1996-06-26 萨依特尔有限公司 作为细胞粘附抑制剂的唾液基Lex类似物
US6054433A (en) 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5785975A (en) 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
AU739673B2 (en) 1997-02-05 2001-10-18 Kirin Pharma Kabushiki Kaisha Lyophilized compositions containing sphingoglycolipid and process for preparing them
EP1520583B1 (en) 1997-04-10 2009-01-28 Kyowa Hakko Kirin Co., Ltd. NKT cell-activating agents containing alpha-glycosylceramides
CA2316041A1 (en) 1997-12-30 1999-07-08 Pam Fredman Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
EP1053243B1 (en) 1998-02-12 2011-03-30 Emory University Sphingolipid derivatives and their methods of use
SE9900496D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
DE60041413D1 (de) * 1999-10-12 2009-03-05 Ca Nat Research Council Archaeosome als adjuvantien und träger für azelluläre impstoffe zur induktion einer zytotoxischen t-lymphozyten (ctl) immunantwort
US20030157113A1 (en) 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
US20030153514A1 (en) 2000-04-28 2003-08-14 Akikuni Yagita Remedies for cancer
JP4410913B2 (ja) 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
WO2001098317A2 (en) 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
AU2001286636A1 (en) 2000-08-25 2002-03-13 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
AU2002327338A1 (en) 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
RU2360699C2 (ru) * 2001-10-03 2009-07-10 Новартис Вэксинес Энд Дайэгностикс Инк. Композиции менингококковых вакцин с адъювантами
CN1578667A (zh) 2001-11-06 2005-02-09 东方癌症治疗株式会社 抗癌组合物
US7273853B2 (en) 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2003105769A2 (en) 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
WO2004094444A1 (en) 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
TWI329130B (en) * 2003-06-19 2010-08-21 Bestewil Holding Bv Functionally reconstituted viral membranes containing adjuvant
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
CA2560969A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
AU2005280163B2 (en) 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
DK1786439T3 (da) 2004-09-03 2010-07-12 Univ Chicago Fremgangsmåder til aktivering af NKT-celler
JP5090928B2 (ja) 2004-12-28 2012-12-05 ザ ロックフェラー ユニバーシティ Ｎｋｔ細胞に対する抗原としての糖脂質及びその類似体
DK1848813T3 (da) 2005-01-28 2013-07-15 Univ Brigham Young Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler
KR100764678B1 (ko) 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
BRPI0617687A2 (pt) 2005-10-25 2011-08-02 Ludwig Inst Cancer Res composto, método para proteger um indivìduo mamìfero contra, ou tratar, um vìrus, infecção microbiana, parasita, uma doença auto-imune, cáncer, alergia ou asma, e, composição farmacêutica
WO2007118234A2 (en) 2006-04-07 2007-10-18 The Scripps Research Institute Modified -galactosyl ceramides for staining and stimulating natural killer t cells
BRPI0621599B1 (pt) 2006-04-27 2021-07-27 Cellid Co., Ltd Vacina baseada em células b carregadas com o ligante da célula t exterminadora natural e antígeno
AU2007269299B2 (en) 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
KR100868959B1 (ko) 2006-12-30 2008-11-17 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물
EP2058011A1 (en) 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
BRPI0820960B8 (pt) 2007-12-05 2021-05-25 Abivax composição, composição farmacêutica, e uso da composição
US9220767B2 (en) 2008-10-08 2015-12-29 Abivax Vaccine composition for use against influenza

Also Published As

Publication number Publication date
HRP20151356T1 (hr) 2016-01-01
AU2008360937A1 (en) 2010-03-04
PL2190475T3 (pl) 2016-04-29
CN101820909A (zh) 2010-09-01
EP2190475A1 (en) 2010-06-02
AU2008360937B2 (en) 2014-01-16
RU2491090C2 (ru) 2013-08-27
KR101540081B1 (ko) 2015-07-29
US8916164B2 (en) 2014-12-23
JP5539890B2 (ja) 2014-07-02
WO2010023498A8 (en) 2010-04-15
AU2008360937B9 (en) 2014-02-13
KR20100072211A (ko) 2010-06-30
EP2190475B1 (en) 2015-10-28
ES2558157T3 (es) 2016-02-02
WO2010023498A1 (en) 2010-03-04
AU2008360937A2 (en) 2010-04-29
JP2011518760A (ja) 2011-06-30
RU2010111766A (ru) 2011-10-10
US20100285042A1 (en) 2010-11-11
PT2190475E (pt) 2016-02-11
BRPI0815846A2 (pt) 2017-05-30

Similar Documents

Publication Publication Date Title
EP1988918A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
ZA200904756B (en) Methods of vaccine administration
ZA200808489B (en) Nicotine-carrier vaccine formulation
IL209027A0 (en) Vaccine compositions and uses thereof
GB0810869D0 (en) Vaccine adjuvant composition
GB0711858D0 (en) Vaccine
ZA200909130B (en) Influenza inhibiting compositions and methods
IL214127A0 (en) Vaccine compositions
GB0900772D0 (en) Live vaccine strains of francisella
EP2334332A4 (en) NEW COMPOSITIONS AND NEW ADJUVANTS
EP2252326A4 (en) VACCINE COMPOSITIONS
EP2498815A4 (en) VACCINE COMPOSITION
GB0805356D0 (en) Vaccine adjuvant composition
GB0710538D0 (en) Vaccine
GB0700135D0 (en) Vaccine
EP2097103A4 (en) VACCINE FORMULATIONS AGAINST INFLUENZA
IL220308A0 (en) Vaccine compositions
PL2190475T3 (pl) Sposoby poprawy właściwości adiuwancyjnych kompozycji szczepionek
EP2337847A4 (en) ADJUVANTS FOR VACCINES
GB0819079D0 (en) Gypsum based formulations
GB0801122D0 (en) Vaccine composition
GB0606856D0 (en) Vaccine compositions
GB0709373D0 (en) BCG-based anti-atheroma vaccine
GB0820404D0 (en) Vaccine compositions
GB0601035D0 (en) Method of vaccine preparation